Clinical trial
Case-Control Viramune (Nevirapine) Toxicogenomics Study
NCT00310843 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00310843 |
|---|---|
| Title | Case-Control Viramune (Nevirapine) Toxicogenomics Study |
| Official title | A Case-Control Toxicogenomics Study to Identify Unique Genetic Polymorphisms in Patients Who Have Experienced Symptomatic Hepatotoxicity or Severe Cutaneous Toxicity Within the First 8 Weeks of Nevirapine Therapy |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Study type | Observational |
| Conditions | HIV Infections |
| Intervention type | Drug |
| Interventions | Nevirapine |
| Enrollment | 889 |
| Start date | Feb 1, 2006 |
| Primary completion | Sep 1, 2008 |
| First posted | Apr 5, 2006 |
| Last update posted | Aug 1, 2013 |
| Countries | Argentina, Australia, Canada, France, Germany, Netherlands, Spain, Taiwan, Thailand, United Kingdom, United States |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: